Enlivex's Phase IIb Allocetra knee osteoarthritis trial clears interim safety review
ENLV•An independent monitoring board reviewed data from 85 randomized, dosed patients in Enlivex's Phase IIb Allocetra trial for primary age-related knee osteoarthritis and found the safety profile allows enrollment to continue as planned. Topline results will be reported in the future.
1. Safety review
An independent monitoring board reviewed interim data from 85 randomized, dosed patients in Enlivex's Phase IIb Allocetra trial for primary age-related knee osteoarthritis. It found the safety profile allowed enrollment to continue as planned; topline results will be reported in the future.




